Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial
Open accessAbstract
BACKGROUND: To present longitudinal changes in Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores during 25-week treatment with enzalutamide or placebo in men with progressive metastatic castration-resistant prostate cancer (mCRPC) after chemotherapy in the AFFIRM trial. PATIENTS AND METHODS: Patients were randomly assigned to enzalutamide 160 mg/day or placebo. FACT-P was completed before randomization, at weeks 13, 17, 21, and 25, and every 12 weeks thereafter while on study treatment. Longitudinal changes in FACT-P scores from baseline to 25 weeks were analyzed using a mixed effects model for repeated measures (MMRM), with a pattern mixture model (PMM) applied as secondary analysis to address non-ignorable missing data. Cumulative distribution function (CDF) plots were generated and different methodological approaches and models for handling missing data were applied. Due to the exploratory nature of the analyses, adjustments for multiple comparisons were not made. AFFIRM is registered with ClinicalTrials.gov, number NCT00974311. RESULTS: The intention-to-treat FACT-P population included 938 patients (enzalutamide, n = 674; placebo n = 264) with evaluable FACT-P assessments at baseline and ≥1 post-baseline assessment. After 25 weeks, the mean FACT-P total score decreased by 1.52 points with enzalutamide compared with 13.73 points with placebo (P < 0.001). In addition, significant treatment differences at week 25 favoring enzalutamide were evident for all FACT-P subscales and indices, whether analyzed by MMRM or PMM. CDF plots revealed differences favoring enzalutamide compared with placebo across the full range of possible response levels for FACT-P total and all disease- and symptom-specific subscales/indices. CONCLUSION: In men with progressive mCRPC after docetaxel-based chemotherapy, enzalutamide is superior to placebo in health-related quality-of-life outcomes, regardless of analysis model or threshold selected for meaningful response. CLINICAL TRIAL NUMBER: NCT00974311.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · see citing works
Self-citationU.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856 · see citing works
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,575 · see citing works
Missing Data in Clinical Studies
Molenberghs, G., & Kenward, M. G. (2007) · Wiley eBooks · doi:10.1002/9780470510445 · Cited by 969 · see citing works
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997) · Urology · doi:10.1016/s0090-4295(97)00459-7 · Cited by 696 · see citing works
Self-citationCella, D. F., Hahn, E. A., & Dineen, K. K. (2002) · Quality of Life Research · doi:10.1023/a:1015276414526 · Cited by 523 · see citing works
Self-citationYost, K. J., & Eton, D. T. (2005) · Evaluation & the Health Professions · doi:10.1177/0163278705275340 · Cited by 382 · see citing works
MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
Siddiqui, O., Hung, H. M. J., & O'Neill, R. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400802609797 · Cited by 301 · see citing works
Assessing and interpreting treatment effects in longitudinal clinical trials with missing data
Mallinckrodt, C. H., Sanger, T. M., Dubé, S., DeBrota, D. J., Molenberghs, G., Carroll, R. J., Potter, W. Z., & Tollefson, G. D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01867-x · Cited by 246 · see citing works
Cella, D. F., Nichol, M. B., Eton, D. T., Nelson, J. B., & Mulani, P. M. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00409.x · Cited by 213 · see citing works
Self-citationBerthold, D., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M. A., Tannock, A. I. F., & on behalf of the TAX-327 investigators (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0944 · Cited by 207 · see citing works
Fizazi, K. S., Scher, H. I., Miller, K., Basch, E., Sternberg, C. N., Cella, D. F., Forer, D., Hirmand, M., & Bono, J. S. D. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70303-1 · Cited by 207 · see citing works
Self-citationRatitch, B., O'Kelly, M., & Tosiello, R. (2013) · Pharmaceutical Statistics · doi:10.1002/pst.1549 · Cited by 155 · see citing works
Basch, E., Autio, K. A., Ryan, C. J., Mulders, P., Shore, N. D., Kheoh, T. S., Fizazi, K. S., Logothetis, C. J., Rathkopf, D. E., Smith, M. R., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70424-8 · Cited by 154 · see citing works
Self-citationToward Patient-Centered Drug Development in Oncology
Basch, E. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1114649 · Cited by 134 · see citing works
MMRM versus MI in Dealing with Missing Data—A Comparison Based on 25 NDA Data Sets
Siddiqui, O. (2011) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543401003777995 · Cited by 63 · see citing works
Kornblith, A. B., Herndon, J. E., Zuckerman, E., Godley, P. A., Savarese, D. M. F., Vogelzang, N., & Holland, J. C. (2001) · Annals of Oncology · doi:10.1023/a:1011102619058 · Cited by 55 · see citing works
Prostate cancer: palliative care and pain relief
Thompson, J. C., Wood, J., & Feuer, D. J. (2007) · British Medical Bulletin · doi:10.1093/bmb/ldm018 · Cited by 32 · see citing works
Yount, S., Cella, D. F., Banik, D., Ashraf, T., & Shevrin, D. H. (2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-69 · Cited by 29 · see citing works
Self-citationMissing Data in Clinical Studies
Hunt, L. P. (2007) · Paediatric and Perinatal Epidemiology · doi:10.1111/j.1365-3016.2007.00889.x · Cited by 29 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00158-4 · Cited by 125 · see citing works
Self-citationFizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119 · see citing works
Self-citation
- Authors
- Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K.
- Affiliations
- Northwestern University (US)
- IQVIA (United Kingdom) (GB)
- Astellas Pharma (United States) (US)
- Université Paris-Sud (FR)
- Corresponding author
- Cella, D.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 26
- Issue
- 1
- Pages
- 179-185
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4269344
- OpenAlex
- W2119529210
- Cited by
- 79
- References
- 21
- Citations by year
- 2026: 1 · 2025: 9 · 2023: 5 · 2022: 3 · 2021: 6 · 2020: 9 · 2019: 4 · 2018: 12 · 2017: 8 · 2016: 12 · 2015: 9 · 2014: 1
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Astellas Pharma Europe
- Astellas Foundation for Research on Metabolic Disorders
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- enzalutamide, metastatic castration-resistant prostate cancer, quality of life, FACT-P, health-related quality of life, docetaxel-based chemotherapy, longitudinal change in quality of life, pattern-mixture models, missing data handling, cumulative distribution function, AFFIRM trial
- MeSH terms
- Docetaxel, Aged, Antineoplastic Agents, Benzamides, Double-Blind Method, Drug Administration Schedule, Humans, Male, Nitriles, Phenylthiohydantoin, Placebos, Quality of Life, Surveys and Questionnaires, Treatment Outcome, Disease-Free Survival, Taxoids, Self Report, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
